- Home
- SIGA vs NGEN Comparison
SIGA vs NGEN Comparison
Compare SIGA & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SIGA | NGEN |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 208.6M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SIGA | NGEN |
|---|---|---|
| Price | $3.46 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 652.0K | 517.9K |
| Earning Date | 05-05-2026 | 04-02-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | $26.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $1.58 |
| 52 Week High | $9.29 | $5.93 |
Technical Indicators
Market Signals| Indicator | SIGA | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 45.00 |
| Support Level | $2.92 | $1.62 |
| Resistance Level | $4.84 | $2.32 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 71.79 | 17.05 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.